Alnylam Pharmaceuticals
ALNY
#631
Rank
C$43.44 B
Marketcap
$335.65
Share price
2.20%
Change (1 day)
68.21%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -C$0.34 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are C$2.24 Billion. , an increase over its 2023 earnings that were of -C$0.44 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 -C$0.33 Billion-24.59%
2023 -C$0.44 Billion-67.84%
2022 -C$1.35 Billion36.93%
2021 -C$0.99 Billion-8.04%
2020 -C$1.07 Billion-15.66%
2019 -C$1.27 Billion12.23%
2018 -C$1.14 Billion62.91%
2017 -C$0.7 Billion17.78%
2016 -C$0.59 Billion43.44%
2015 -C$0.42 Billion60.69%
2014 -C$0.26 Billion98.2%
2013 -C$0.13 Billion
2011 -C$76.05 Million27.48%
2010 -C$59.65 Million-10.92%
2009 -C$66.97 Million95.77%
2008 -C$34.21 Million
2006 -C$54.8 Million-9.13%
2005 -C$60.31 Million34.74%
2004 -C$44.76 Million36.79%
2003 -C$32.72 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-C$0.84 Billion 154.87%๐Ÿ‡บ๐Ÿ‡ธ USA
C$6.63 B-2,129.54%๐Ÿ‡บ๐Ÿ‡ธ USA
C$0.36 B-210.72%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$14.38 Million-95.60%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$64.09 Million-80.38%๐Ÿ‡บ๐Ÿ‡ธ USA
C$18.92 B-5,891.51%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
C$11.01 B-3,472.17%๐Ÿ‡ซ๐Ÿ‡ท France
-C$0.4 Billion 19.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel